Journal of psychoactive drugs最新文献

{"title":"Utilizing Psychedelics to Enhance Well-Being: A Systematic Review.","authors":"Samuel Thomson, Nikos Thomacos","doi":"10.1080/02791072.2025.2484380","DOIUrl":"https://doi.org/10.1080/02791072.2025.2484380","url":null,"abstract":"<p><p>Psychedelic-assisted therapy is gaining recognition for its potential to enhance human functioning. While most research has focused on psychedelic' therapeutic use for mental illness, this review applies the PERMA Theory of Well-Being to systematically examine their role in enhancing well-being in healthy individuals. The final search of five academic databases was conducted on February 4, 2024, including studies published from 1994. After applying the inclusion criteria (controlled or naturalistic experimental design with an outcome measurement at least 7 days post-consumption), 19 studies were included. Encompassing 949 participants, two studies involved 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), seven ayahuasca, two lysergic acid diethylamide (LSD), and eight psilocybin. Results consistently indicate psychedelic consumption is related to enduring enhancements in PERMA's five elements of well-being, including positive emotions, engagement, relationships, meaning, and accomplishment. While discussion of adverse effects was frequently absent, no serious adverse effects were reported in six studies. Future research should address the limitations of the included studies by conducting larger-scale, longitudinal randomized controlled trials that incorporate a comprehensive assessment of well-being. Nevertheless, the findings of this systematic review call for a paradigm shift, moving beyond a disease-focused lens to recognizing psychedelics' capacity to enhance well-being in healthy individuals, ultimately fostering human flourishing.</p>","PeriodicalId":16902,"journal":{"name":"Journal of psychoactive drugs","volume":" ","pages":"1-17"},"PeriodicalIF":2.1,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143753256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors of Psychoactive Substance Use Behaviors and Intention Among Social Workers' Adolescent Case-Work Clients in Hong Kong.","authors":"Yanqiu Yu, Nick Tse, Tsun Kwan Mary Ip, Phoenix K H Mo, Joseph T F Lau","doi":"10.1080/02791072.2025.2483701","DOIUrl":"https://doi.org/10.1080/02791072.2025.2483701","url":null,"abstract":"<p><p>Based on Social Cognitive Theory (SCT), this study investigated the factors of psychoactive substance use in terms of current use (past 30 days), lifetime use, and behavioral intention (next 12 months) in Hong Kong adolescent case-clients of social workers from July 2021 to June 2022. The prevalence of current/lifetime psychoactive substance use and behavioral intention to use psychoactive substances was 7.6%/20.9% and 8.6%, respectively. The SCT constructs of positive outcome expectancy of psychoactive substance use, the observational learning indicators, and the environmental factor (easiness to obtain psychoactive substances) were positively associated with current and lifetime psychoactive substance use. Similar associations involving negative outcome expectancy (NOE), emotional relief refusal self-efficacy (RSE), and opportunistic RSE were significant and negative. Furthermore, NOE, emotional relief RSE, and social facilitation RSE were significantly associated with behavioral intention of psychoactive substance use. Future longitudinal studies are warranted to confirm the findings and test pilot interventions.</p>","PeriodicalId":16902,"journal":{"name":"Journal of psychoactive drugs","volume":" ","pages":"1-10"},"PeriodicalIF":2.1,"publicationDate":"2025-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143753254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Construction and Standardization of Perceived Shame Scale for Young Adults with Paternal Substance Use Disorder in Pakistan.","authors":"Muhammad Nasar Iqbal, Shirmeen Ijaz, Zohaib Ahmed, Fatima Javed, Mujahid Iqbal","doi":"10.1080/02791072.2025.2484378","DOIUrl":"https://doi.org/10.1080/02791072.2025.2484378","url":null,"abstract":"<p><p>Young adults who struggle with paternal substance use disorder frequently experience elevated levels of shame, which are a result of both internalized feelings of inadequacy and societal stigma. This study aims to develop and validate a perceived shame scale with paternal substance use disorder. This study comprises two phases. Phase I involves the development of the perceived shame of paternal substance use disorder scale, and Phase II aims to validate this scale. This study employed a mixed-method research design and purposive sampling technique was used to collect data from 340 participants for exploratory factor analysis (EFA) and 300 participants for confirmatory factor analysis (CFA). Participants, aged 20-30 years (<i>M = 25.12, SD = 3.05</i>) were recruited. The results finalized twenty-two (22) items with four sub-scales after CFA i.e. psychological problems, interpersonal problems, existential problems, and social problems demonstrating excellent validity and reliability. In conclusion, the results provide a useful tool for future research and clinical interventions aimed at addressing paternal substance use disorder and related emotional difficulties, in addition to furthering our understanding of the internalized and societal causes of shame. The findings of this study have important ramifications for developing empathy, lowering stigma, and advancing efficient support networks for those dealing with this difficult problem.</p>","PeriodicalId":16902,"journal":{"name":"Journal of psychoactive drugs","volume":" ","pages":"1-9"},"PeriodicalIF":2.1,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143719832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of Recreational Cannabis Legalization with Frequency of Using Cannabis for Sleep.","authors":"Zoë Panchal, Joseph T Sakai, Jarrod M Ellingson, Stephanie Zellers, Kenneth P Wright, Matt K McGue, Scott Vrieze, John K Hewitt, Robin P Corley, William Iacono, Christian J Hopfer, J Megan Ross","doi":"10.1080/02791072.2025.2484379","DOIUrl":"https://doi.org/10.1080/02791072.2025.2484379","url":null,"abstract":"<p><p>We examined the association of recreational cannabis legalization (RCL) with frequency of using cannabis, alcohol, and sleep medication for sleep and with co-use of cannabis with other sleep aids. We used linear regression models to examine these associations in a population-based sample of adult twins (<i>n</i> = 3,141). Participants (M_age = 37 (SD = 5)) were primarily White (93%), with 5% Hispanic/Latinx, and female (61%). RCL was associated with using cannabis for sleep more frequently even after controlling for cohort, demographics, sleep quality, anxiety, depression, physical health, season, and pre-legalization cannabis use frequency (β = 0.123, <i>p</i> = .001). RCL was not associated with frequency of using alcohol or sleep medication for sleep, or with co-use of cannabis and other sleep aids. More research is needed to determine whether RCL leads to more frequent use of cannabis for sleep.</p>","PeriodicalId":16902,"journal":{"name":"Journal of psychoactive drugs","volume":" ","pages":"1-10"},"PeriodicalIF":2.1,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143730692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cannabis and Cocaine, Heroin, or Methamphetamine Use and Factors Associated with Multiple Drug Use and Drug Treatment in a Nationally Representative Sample.","authors":"Ellen T Kurtzman, Christine Ramdin, Lewis S Nelson","doi":"10.1080/02791072.2025.2484389","DOIUrl":"https://doi.org/10.1080/02791072.2025.2484389","url":null,"abstract":"<p><p>Cannabis is often used with other illicit drugs. Drawing from leading theories of polysubstance use, we used data from the 2009-2018 National Health and Nutrition Examination Survey to examine the prevalence of reported lifetime use of cannabis and cocaine, heroin, and/or methamphetamine among non-pregnant respondents ages 18-59 years. After identifying the subpopulation that reported using multiple drugs, we used multivariate logistic regression analysis to identify their demographic characteristics and factors associated with drug treatment participation. Within our analytic sample (<i>N</i> = 16,946), 18.7% reported lifetime cannabis use and cocaine, heroin, or methamphetamine use; 1.4% reported using all four of these drugs in their lifetime. Among individuals who reported using multiple drugs, 21.3% reported drug treatment participation. Compared to respondents who had never been in drug treatment, those who had been had higher odds of being non-Hispanic Black (AOR = 2.0, 95% CI 1.5-2.8), being in fair/poor health (AOR = 1.5, 95% CI 1.1-1.9), and reporting more medical conditions (AOR = 1.2, 95% CI 1.1-1.4). Being female, Mexican American, married, and a non-citizen lowered the odds of drug treatment. Having more than a high-school education and having a household income of more than $100,000 also reduced the odds of drug treatment.</p>","PeriodicalId":16902,"journal":{"name":"Journal of psychoactive drugs","volume":" ","pages":"1-13"},"PeriodicalIF":2.1,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143719806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perceived Importance of Counseling Among Patients Receiving Methadone Treatment.","authors":"Declan T Barry, Mark Beitel, Marina Gaeta Gazzola, Suneel Agerwala, Gul Saeed, Kathryn F Eggert, Teresa Roehrich, Connie Hsaio, Mikah Covelli, Iain D Carmichael, Lynn M Madden, Muhammad Hammouri","doi":"10.1080/02791072.2025.2484374","DOIUrl":"https://doi.org/10.1080/02791072.2025.2484374","url":null,"abstract":"<p><p>We examined the perceived importance of counseling and its correlates among patients receiving methadone treatment (MT). Participants were 345 patients attending MT who completed 7-point Likert-type scales from 1 (\"Strongly Disagree\") to 7 (\"Strongly Agree\") to rate agreement with perceived importance of counseling, opioid use disorder (OUD) illness models, and OUD treatment beliefs. We examined predictors of perceived importance of counseling using hierarchical linear regression; steps 1, 2, and 3 were demographics, OUD illness models, and OUD treatment beliefs, respectively. Most (76%) agreed counseling was important (Mean = 5.6, SD = 1.7). Demographics did not contribute significantly to the regression model, F(4, 340) = 0.88, <i>p</i> > .05). R² was significant for Step 2 (F = 2.89, <i>p</i> < .05) but individual OUD illness model variables did not make a significant contribution (F(3, 337) = 1.76, <i>p</i> > .05). The addition of OUD treatment beliefs on Step 3 (positive overall treatment expectation, importance of daily methadone, life-saving benefit of methadone medication, and importance of mutual aid) explained an additional 51% of the variation in perceived importance of counseling and this change in R² was significant, F(4, 333) = 31.17, <i>p</i> < .001. We conclude that most participants perceived counseling to be important and OUD treatment beliefs independently predicted perceived importance of counseling.</p>","PeriodicalId":16902,"journal":{"name":"Journal of psychoactive drugs","volume":" ","pages":"1-8"},"PeriodicalIF":2.1,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143719882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patterns of Tobacco Use, Dependence, and Motivation to Quit Among Individuals Seeking Treatment for Alcohol and Cannabis Consumption in Catalonia (Spain).","authors":"Cristina Martinez, Judith Saura, Marta Enriquez, Ariadna Feliu, Xavier Roca, Yolanda Castellano, Carmen Cabezas, Josep Maria Suelves, Silvia Mondon, Pablo Barrio, Magali Andreu, Antonia Raich, Francina Fonseca, Laura Masferrer, Pablo Bautista, Esteve Fernandez","doi":"10.1080/02791072.2025.2479102","DOIUrl":"https://doi.org/10.1080/02791072.2025.2479102","url":null,"abstract":"<p><p>Understanding smoking behaviors in vulnerable groups is essential for effective cessation services. This study characterizes tobacco consumption and identifies factors associated with nicotine dependence and motivation to quit among individuals entering alcohol and cannabis treatment programs. A multi-center cross-sectional study was conducted in ten centers in Barcelona province. Participants' sociodemographics and tobacco use were assessed, including cigarette consumption and nicotine dependence (Fagerström test). Self-efficacy and motivation to quit were measured on a 0-10 Likert scale. A decision-tree analysis identified factors linked to moderate-to-high nicotine dependence (Fagerström ≥ 5) and high cessation motivation (≥7). Most participants (96.1%) use tobacco daily, with 57.0% using manufactured and 42.2% roll-your-own (RYO) cigarettes. Mean cigarette consumption was 15.2/day (SD = 8.7), with nicotine dependence (4.4, SD = 2.3). Cannabis users started smoking tobacco earlier than those who used alcohol. Over the past year, two-thirds attempted quitting and 60% had high cessation motivation. Self-efficacy for quitting was moderate (mean = 5.1; SD = 3.3). RYO use, age over 45, and alcohol use were associated with moderate-to-high nicotine dependence (probabilities = 0.52, 0.62, and 0.71, respectively). Having a non-tobacco social network was linked to a high motivation to quit (probability = 0.72). Participants had moderate nicotine dependence, low self-efficacy, and high motivation to quit tobacco. Dependence was higher among RYO users, ≥45 years/old, and people with alcohol use disorder. High motivation was more frequent among those with a non-tobacco social network. Integrating cessation support into substance treatment, focusing on RYO and young users, and promoting self-efficacy and tobacco-free socialization may enhance cessation success.</p>","PeriodicalId":16902,"journal":{"name":"Journal of psychoactive drugs","volume":" ","pages":"1-15"},"PeriodicalIF":2.1,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143710380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differences in Online Descriptions and Marketing of Derived Intoxicating Cannabis Products.","authors":"Cassidy R LoParco, Carlton Bone, Ashvita Garg, Carla J Berg, Matthew E Rossheim","doi":"10.1080/02791072.2025.2484376","DOIUrl":"https://doi.org/10.1080/02791072.2025.2484376","url":null,"abstract":"<p><p>Given the rapid expansion of the derived intoxicating cannabis product (DICPs) market and product diversity, this study assessed marketing information provided by online retailers regarding specific DICP compounds. In May 2023, we searched \"buy delta thc\" in Google's incognito, selected the 20 most trafficked online retailers, and assessed product descriptions and related marketing claims across DICP compounds. 18/20 websites provided descriptions for various DICPs. The top five themes were psychoactive/intoxicating profile (100% of the 18 sites), physical effects (94%), mental effects (94%), naturalness (83%), and safety recommendations (83%). All DICPs, except for THCA and HHC-O, were described as psychoactive/intoxicating; potency was often discussed in relation to delta-9 or delta-8 THC. Claims related to physical effects included improvements to general health, pain management, sleep/insomnia aid (mostly for delta-9 THC). Each compound was described on at least 1 website as having relaxing/calming effects; all compounds except for THCP were described as having anti-anxiety effects. Safety recommendations included buying from trusted/reputable sources; 12 websites mentioned compounds \"suitable for new users\" (deltas-8,9,10 THC, HHC, THCP, THCV). Findings highlight potentially misleading information in DICP marketing and the need for stricter regulatory oversight, as well as required health warnings to protect and educate consumers.</p>","PeriodicalId":16902,"journal":{"name":"Journal of psychoactive drugs","volume":" ","pages":"1-11"},"PeriodicalIF":2.1,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143700587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mixed-Methods Study of Use and Attitudes About Psychedelics for Therapeutic Purposes Among Low-Income U.S. Veterans Nationally.","authors":"Jack Tsai, Laura Witte, Taylor Fate","doi":"10.1080/02791072.2025.2483705","DOIUrl":"https://doi.org/10.1080/02791072.2025.2483705","url":null,"abstract":"<p><p>There is great public and clinical interest in the use of psychedelics for therapeutic purposes. However, there has been little national study of psychedelic use in the U.S. veteran population. This study used quantitative and qualitative data from a nationally representative survey of 1,031 low-income U.S. veterans who participated in the National Veteran Homeless and Other Poverty Experiences (NV-HOPE) Study in 2023. In the total sample, lifetime prevalence of psychedelic use for therapeutic purposes was 5.6%, and 23.2% believed psychedelics should be legalized for therapeutics. Veterans who reported more behavioral health issues (e.g. mental and substance use disorders) and had a history of psychosocial problems (e.g. homelessness) were more likely to have used psychedelics for therapeutic reasons and more likely to endorse legalization of psychedelics as therapeutics. Qualitative data revealed mixed attitudes with positive attitudes related to personal experiences and beliefs in the potential benefits of psychedelics, while negative attitudes related to concerns about risks of psychedelics and doubts about their treatment effectiveness. These findings highlight opportunities to use psychedelics as therapeutics among low-income veterans, particularly for those with behavioral and social problems. There is also moderate support in this population toward legalization of psychedelics for therapeutic purposes.</p>","PeriodicalId":16902,"journal":{"name":"Journal of psychoactive drugs","volume":" ","pages":"1-10"},"PeriodicalIF":2.1,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143691837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of the Prescribing of Attention-Deficit Hyperactivity Disorder Medication During Pregnancy: A Systematic Review.","authors":"Danielle J Russell, Ebony Quintrell, Caitlin S Wyrwoll, Erin Kelty","doi":"10.1080/02791072.2025.2478085","DOIUrl":"10.1080/02791072.2025.2478085","url":null,"abstract":"<p><p>Attention deficit hyperactivity disorder (ADHD) diagnosis in women has markedly increased in recent years, resulting in an increase of ADHD medication exposure during pregnancy, which has uncertain health risks. It is therefore critical to understand the extent of the issue. The objective of this novel systematic review was to investigate the prevalence of the prescribing of ADHD medication during pregnancy. A systematic review was conducted following preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines. The last search was October 13, 2023, for articles examining the prescribing of ADHD medication in pregnancy. Fifteen studies were included. Participants from the United States (<i>n</i> = 4), the Nordic countries (<i>n</i> = 10), Canada (<i>n</i> = 3), and Australia (<i>n</i> = 1) were included. The prevalence of ADHD-medication dispensing during pregnancy ranged from 0.07 to 6.01 per 1,000 pregnancies. Typically, stimulant medications were more prevalent than nonstimulants. The most prevalent ADHD medication dispensed during pregnancy was methylphenidate followed by amphetamine-type medications. There was high heterogeneity (I² = 99.95%) between the studies, making the study data not appropriate for meta-analysis. The prevalence of the prescribing of ADHD medications in pregnancy ranged substantially, with psychostimulant medications most prescribed. Apart from in the Nordic countries, estimates of prevalence were limited.</p>","PeriodicalId":16902,"journal":{"name":"Journal of psychoactive drugs","volume":" ","pages":"1-11"},"PeriodicalIF":2.1,"publicationDate":"2025-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143692394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}